Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor (NCT05523947)
A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Who can join: Review the eligibility criteria below.
Location: Dana Farber Cancer Institute — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Dana Farber Cancer Institute — Boston, Massachusetts
- Vanderbilt Ingram Cancer Center — Nashville, Tennessee
- Southern Oncology Clinical Research Unit — Adelaide,
- Austin Health — Melbourne,
- Breast Cancer Research Centre - WA — Perth,
- Blacktown Hospital — Sydney,
- CHA Bundang Medical Center — Seongnam-si, Gyeonggi-do
- Catholic University of Korea St. Vincent's Hospital — Suwon, Gyeonggi-do
- Ajou University Hospital — Suwon, Gyeonggi-do
- Gyeongsang National University Hospital — Jinju, Gyeongsangnam-do
- Chungbuk National University Hospital — Cheongju-si, North Chungcheong
- Gachon Gil University Medical Center — Incheon,
- Korea University Anam Hospital — Seoul,
- Seoul National University Hospital — Seoul,
- Severance Hospital, Yonsei University Health System — Seoul,
- Asan Medical Center — Seoul,
- Samsung Medical Center — Seoul,
- The Catholic University of Korea, St. Mary's hospital — Seoul,
- Ulsan University Hospital — Ulsan,
📞 Contact the Study Coordinator
Phone: (822) 828-0065
Email: clinicaltrials@yuhan.co.kr
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All HER2-Positive Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.